Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.44 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.44 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.44 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.44 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PLK1 | P53350 | 5/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.40 |
| ▸ | GSK3A | P49840 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6989283 | 0.86 | ABCC9 (0.51) | GAAMAPKAPK2ABCC9ABCC8KCNJ11 | |
| SCHEMBL6983541 | 0.85 | MAPKAPK2 (0.52) | MAPKAPK2ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL7555212 | 0.84 | ABCC9 (0.51) | MAPKAPK2ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6981921 | 0.84 | ABCC9 (0.64) | MAPKAPK2ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6990454 | 0.83 | ABCC9 (0.52) | MAPKAPK2ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6988178 | 0.82 | NAMPT (0.52) | MAPKAPK2ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6991578 | 0.82 | ABCC9 (0.51) | MAPKAPK2ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6987212 | 0.81 | NPC1 (0.41) | MAPKAPK2ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6984652 | 0.81 | ABCC9 (0.51) | MAPKAPK2ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6987810 | 0.81 | ABCC9 (0.47) | MAPKAPK2ABCC9ABCC8KCNJ11KCNJ8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6495576-B2 | N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | claimed |
| US-20020165264-A1 | Aminal diones as potassium channel openers | ABBOTT LABORATORIES | 2002-11-07 | — | — | US | claimed |
| US-20020147230-A1 | Aminal Diones as potassium channel openers | ABBOTT LABORATORIES | 2002-10-10 | — | — | US | claimed |
| EP-1358160-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6495576-B2 | N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | disclosed |
| US-20020165264-A1 | Aminal diones as potassium channel openers | ABBOTT LABORATORIES | 2002-11-07 | — | — | US | disclosed |
| US-20020147230-A1 | Aminal Diones as potassium channel openers | ABBOTT LABORATORIES | 2002-10-10 | — | — | US | disclosed |
| WO-2002062761-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147230-A1 | Aminal Diones as potassium channel openers | KCNJ2, KCNJ11, KCNH1 | GFER 774/4885GAA 2105/4885MAPKAPK2 2283/4885 |
| US-20020165264-A1 | Aminal diones as potassium channel openers | KCNJ2, KCNJ11, KCNH1 | GFER 774/4885GAA 2105/4885MAPKAPK2 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.